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There is a clear need for new methods of treatment of acute disc herniation in dogs,
most obviously to address the permanent loss of function that can arise because of the
associated spinal cord injury. Clinical trials form the optimal method to introduce new
therapies into everyday clinical practice because they are a reliable source of unbiased
evidence of effectiveness. Although many designs are available, parallel cohort trials are
most widely applicable to acute disc herniation in dogs. In this review another key trial
design decision—that between pragmatic and explanatory approaches—is highlighted
and used as a theme to illustrate the close relationship between trial objective and design.
Acute disc herniation, and acute spinal cord injury, is common in dogs and there is
a multitude of candidate interventions that could be trialed. Most current obstacles to
large-scale clinical trials in dogs can be overcome by collaboration and cooperation
amongst interested veterinarians.
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INTRODUCTION
Introduction of new medical interventions into everyday practice requires assessment of safety,
effectiveness and, preferably, comparison with currently available therapies. These assessments are
undertaken in the form of clinical trials. The typical process for clinical trial development follows
a series of phases. Phase 0 trials involve a small number of subjects and often represent the first
exposure of a drug or intervention to the target species, with the goal of learning how a drug
interacts with the target. Phase I trials are typically “dose finding” studies that aim to define the
optimum dose or regimen for therapy as well as delineating safety and defining toxicities associated
with a new treatment in a healthy and, sometimes, a diseased population. Phase II and III trials have
the goal of further establishing safety in the target population, assessing effectiveness or efficacy, and
then validating those findings in larger populations of patients with the disease of interest.
Phase II and III randomized controlled trials (RCTs) are the “gold standard” for assessment of
impact and are rigorously planned clinical experiments designed to minimize all sources of bias
(1). There are many trial designs within this category, but the most common is the parallel group
trial in which a population of affected participants is randomly allocated to receive either the novel
intervention or the standard-of-care therapy (or placebo). The outcome of interest is thenmeasured
at a specified time after the intervention and the numbers or proportion of responders, or mean
response, compared between groups. Although all clinical trial phases are important for therapeutic
development in the context of spinal cord injury for dogs with intervertebral disc herniation, the
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focus of this review will be on Phase II and Phase III studies, with
some mention of the Phase I studies in terms of the preparatory
data they provide.
EXPLANATORY VS. PRAGMATIC
Clinical trials can also be categorized according to whether
they aim to be explanatory or pragmatic, and this distinction
is important because it provides critical underpinning to
the way that trials are designed. This dichotomy in aim
is often overlooked in veterinary medicine but will provide
a theme throughout this review (2). There is a range of
criteria by which to decide whether a trial is pragmatic or
explanatory (3) and many trials do contain aspects of both
aims. However, fundamentally an explanatory trial aims to
determine whether an intervention will work under ideal
circumstances (i.e., “can this intervention work?”), whereas
a pragmatic trial aims to determine if there is a benefit
when it is applied in everyday practice (4). This difference
has a multitude of secondary implications, most notably the
tendency to strictly limit participant entry in explanatory
trials and to restrict analysis to only those participants that
completed every component of intervention and outcome
measurement. On the whole, pragmatic trials are likely to have
greater impact in everyday clinical medicine, because they have
broader application.
There is often tension between these two approaches for
veterinarians carrying out trials of interventions for spinal cord
injury in dogs, because pragmatic trials would tend to be more
useful for veterinary clinicians, whereas explanatory trials tend to
be more useful in answering questions that arise from the “basic
science” of spinal cord injury. In this context, an explanatory
trial might tightly limit lesion location, injury severity, time since
onset of injury and have detailed and complex outcomemeasures.
All of these aspects might be matched with the tightly-controlled
circumstances in which the intervention was previously applied
in experimental animals, thereby providing a “proof of principle”
that the intervention can translate from laboratory to clinic. Such
a trial is more likely to find favor with a “basic science” spinal
cord injury researcher. Nevertheless, researchers interested in
developing interventions that can be translated from laboratory
to clinic would also need to be cognizant that an intervention that
works in a limited patient population under ideal circumstances
and with a complex outcome measure used to detect benefit
might not necessarily have useful clinical impact in humans—
or pet dogs—with spinal cord injury. In contrast, a pragmatic
trial might include all cases of thoracolumbar spinal cord injury
and might focus its outcome measures on owner judgement
of each animal’s level of function and perceived quality of life.
This type of trial will more likely find favor with veterinarians
treating such cases, and also with researchers who have a strong
interest in translational research: if an intervention can still show
effectiveness even when used in sub-optimal circumstances it is
likely to be sufficiently robust to translate into human spinal cord
injury. The downside to this type of trial is that it may be difficult
to understand why a treatment fails in a pragmatic trial; the loose
inclusion criteria and outcome assessments may obscure a real
effect that is lost in the noise of other competing effects.
Both explanatory and pragmatic trials have value and, in
practice, many trials will incorporate aspects of both study
aims; nevertheless, it is critical to consider these two, sometimes
conflicting, aims during the design process.
KEY ELEMENTS OF A RANDOMIZED
CONTROLLED TRIAL
The classic design of Phase II/III RCT may be explanatory or
pragmatic and hasmany prerequisites, notably random allocation
of individuals to experimental and control groups, concealment
of allocation before enrolment, assessment of follow-up by
blinded observers, pre-specified definition of outcome assessment
methods and comparisons and, usually, enrolment of large groups
of participants (so as to be able to apply effective randomization).
Best practices in the design of RCT have been formalized and
published in human medicine under the recommendations of
the CONSORT statement (http://www.consort-statement.org/),
and this set of guidelines can also readily be applied to veterinary
clinical trials.
An important ethical consideration before undertaking an
RCT, is whether there is clinical “equipoise.” A state of equipoise
exists if there is a balance of expert opinion between the
two interventions that are being assessed in terms of their
effectiveness, or if there is a degree of uncertainty across the
field with respect to the efficacy of a particular intervention (5).
For instance, although there is evidence that fenestration alone
provides similar functional outcomes as decompressive surgery
for “deep pain positive” pelvic limb paralysis or paresis following
acute thoracolumbar intervertebral disc herniation (6), the expert
consensus is that there IS a difference in outcome between these
interventions. Therefore, a trial comparing these two options
would not currently be considered ethical because expert opinion
does not consider them equal in value. Although decompressive
surgery has not been proven as the standard of care through a
RCT, it has become so by default through synthesis of other types
of evidence and through expert opinion.
For a variety of reasons, many aspects of RCTs can be difficult
to achieve in veterinary medicine and, in general, there are
few reported large-scale RCTs in animals [although note (7)].
However, a small number of clinical trials have already been
carried out in dogs with acute and chronic spinal cord injury,
most of which take an explanatory approach to trial design.
Because one of the ultimate goals of CANSORT-SCI is to provide
data on dogs with spinal cord injury that can lead to new
therapies effective at the population level, the emphasis in this
overview will be on construction of large-scale pragmatic trials,
a design so far used less commonly in veterinary medicine but
most likely to change how spinal cord-injured dogs are handled
in future.
When considering an RCT there are several key questions
to answer:
◦ Does the trial aim to be explanatory or pragmatic?
◦ What population will be examined?
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◦ What intervention will be applied?
◦ What will the comparator be?
◦ What outcome measure will be used?
◦ What degree of improvement will be detected? (Including its
clinical impact).
SELECTION OF CASES
Although there is much to be learned about how best to treat
dogs with spinal cord injuries of all types, those that have
incurred acute thoracolumbar disc herniation are most in need
of new therapies. This is partly because it is the most common
type of injury (8), and partly because there is a recognized
poor prognosis for dogs in some sub-categories of this cohort
(9, 10). The main impetus that drives the perceived need for
a new therapy for spinal cord injury in dogs is the lower
proportion of dogs that recover locomotion (and other functions)
after presenting with loss of “deep pain sensation” following
acute thoracolumbar intervertebral disc herniation. In this sub-
group, the proportion that recover independent quadrupedal
locomotion is usually estimated to be around 55%, in contrast to
the estimated 90–95% recovery for dogs that present with “deep
pain sensation” intact (6, 10, 11). Furthermore, most of these
deep pain negative dogs do not recover appropriate autonomic
function either. It is currently a major source of frustration for
owners and veterinarians alike that we cannot offer anything
better for these patients and so this review will focus on this
specific sub-set.
Refining Inclusion Criteria
As well as having a clear clinical need for new therapy, dogs
that present as “deep pain negative” can almost immediately
be identified as potential trial candidates. However, although
these cases can be rapidly recognized, it is important to note
that this group is not homogenous. Such “deep pain negative”
cases have variable duration and rate of onset, delay before
presentation, severity of compression and inter-animal variation
in body weight or conformation and so they can be further
sub-divided if necessary, and this choice might be guided by
deciding whether the trial has pragmatic or explanatory aims.
For instance, it could be considered that a trial to investigate a
putative therapy should be restricted to dogs that present within a
specific time window and are of a specific age (i.e., leaning toward
a more explanatory design). The advantage of investigating
treatment effects in a sub-group of the whole population is
that if they are more homogenous then the signal-to-noise ratio
of any treatment effect can be more readily discerned. The
drawback is that the proportion of cases within each sub-group
will of course be smaller than the total population, so causing
more difficulties with case recruitment adequate to achieve the
prerequisite sample size.
Questions can also be asked about whether to restrict entry to
a trial to specific types or sizes of dog. An important corollary
is that, strictly, trial results only guide treatment of similar types
of patient in the future. For instance if a drug for diabetes (in
people) was successful in trials in obese males over 50 years old,
there might be doubt about whether the results might apply to
underweight 15 year old female patients. This aspect of clinical
trial interpretation is known as the generalizability (1) and must
be used to inform design. For dogs with spinal cord injury
after intervertebral disc herniation the majority of cases will
be middle-aged chondrodystrophic dogs and so there might be
merit in restricting trial entry to these cases. The results could
then be used to apply to the most commonly affected patients in
future. On the other hand, if a 4 year-old German shepherd were
to present with an acute herniation in future then we might not
necessarily expect the same results as were obtained in the trial.
The alternative to restricting trial entry is to set up a
more pragmatic trial, in which all-comers can be included. A
possible drawback to more eclectic enrolment, especially when
considering spinal cord injury in dogs, is that the trial arms
easily become unbalanced through inclusion of relatively unusual
cases (because they may randomize to one or other arm only),
unless large numbers of cases are included. Another aspect of
specific case selection that might apply regarding dog size is the
widespread perception that recovery is different between large
and small dogs (12). Again, if the treatment groups are sufficiently
large this does not cause a problem—large dogs can be assumed
to randomize equally to the two arms of the trial.
Although there is reason to think that deep pain negative dogs
constitute the group most in need of new therapy, it could also be
questioned whether there might be a need to investigate whether
the recovery rate for dogs that are deep pain positive might also
be enhanced. This enhanced recovery might take the form of a
greater proportion recovering to walk or that the recovery could
be made more rapid or more complete. Because of the inherent
need for more complex outcome measures for these patients, it
is likely that designs for studies on these dogs will be explanatory
rather than pragmatic.
INTERVENTION
Selection of test interventions in clinical trials is usually based
on pre-clinical data, which have generally been derived in
experimental animals. When applied to human clinical trials,
the steps toward a Phase II/III RCT would usually include a
Phase 0 or Phase I “first-in-human” trial to assess toxicity and,
depending on the nature of the intervention, often also include
pharmacokinetic and pharmacodynamic studies to determine
optimal dosing regimens. Appropriate surgical or physical
therapy interventions are often less formally assessed at the pre-
clinical stage because the relevant procedures may not be feasible
or appropriate in experimental animal subjects. Traditionally,
new therapeutic interventions in veterinary medicine are often
derived from human medicine, but in spinal cord injury there
are no therapies available for treatment of humans that are
not available for dogs. In both species, treatment consists of
care to maintain blood pressure, spinal cord decompression,
and vertebral stabilization if appropriate, physical therapy and
allowing plenty of time for nervous system recovery and plasticity
(10, 13, 14).
There is a huge number of interventions that could potentially
be applied to dogs with spinal cord injury, many of which have
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been extensively tested in laboratory animals over many years
[e.g., (15–17)]. The decision as to which to select for further
evaluation through RCTs in clinical cases might be determined
by many factors, most notably knowledge about toxicity, the
feasibility of appropriate dosing and the feasibility of application
within a time period in which the agent has been shown to be
effective. For instance, although tetrodotoxin can reduce the loss
of spinal cord tissue and function after injury (18) it has very
serious potential toxicity and was ineffective when applied 4 h
after injury (19). Unfortunately, only about 15% of canine cases
of spinal cord injury are presented to a specialty care facility
within 8 h, with a much small proportion likely presented within
4 h; therefore, most cases cannot be treated at an appropriate
specialist center within such a short period after injury (20).
Alternatively, if we were to consider that suitable cases for a
clinical trial were dogs that had chronic spinal cord injury—
i.e., that they had an acute spinal cord injury from which they
made an incomplete recovery—then the time period for the
intervention becomes much less critical and a different series of
intervention options is available.
Of the multitude of available medication interventions that
might be useful based on reported success in laboratory animal
models, many could plausibly be converted into clinical therapies
in dogs. It is reasonable to consider that a credible subject for a
RCT in dogs would be one that has shown benefits in experiments
in more than one laboratory and more than one model of injury.
Prominent examples of medications that meet these criteria and
could be used acutely as neuroprotective strategies for spinal cord
injury include riluzole (21), glyburide (22), andminocycline (17),
all of which have been the focus of (Phase I or Phase II) clinical
trials in people (see ClinicalTrials.gov). Again, it must be asked
whether any of these agents can be applied rapidly enough after
the injury in pet dogs, for which the median time to presentation
is 24 h, to be beneficial (20).
In terms of surgical interventions, there is accumulating
evidence that durotomy/duroplasty may be of value in reducing
the intraparenchymal spinal cord pressure (thereby improving
blood flow) in humans (23), experimental animals (24) and,
recently, clinical canine patients (25, 26). This intervention has
the benefit of being applicable for many hours, or even days,
following an acute spinal cord injury and so could readily
be translated into clinical veterinary practice. Currently there
is clinical equipoise regarding this intervention, with closely
balanced evidence for and against.
None of the interventions mentioned above are complicated
to apply and so could all be used within pragmatic and
explanatory trial frameworks.
COMPARATOR
The comparison therapy for dogs entered into a RCT to
test an intervention for acute spinal cord injury would be
“standard care,” which would consist of cross-sectional imaging
and decompressive surgery (9, 10). Placebo therapy would
not be a credible (nor ethical, see below) option in view of
current clinical thinking and in some jurisdictions (the UK)
is not permitted. Even so, “standard care” is not well-defined,
especially in terms of anesthesia protocols, fluid therapy before
and during surgery and, especially, post-operative care and
physical therapy.
Therefore, other peri-operative therapies might require
recording, or might require controlling through defined
inclusion/exclusion criteria, when investigating a new
intervention, although, again, the need to limit would be
determined by how much the balance lay toward an explanatory
approach. It is possible that some routine interventions might
impact the results or interact with the trial therapy. There is some
limited evidence that physical therapy for spinal cord-injured
humans can have an impact on outcome (27, 28). Some data
suggest benefits in dogs too (29), although a previous RCT on
this subject did not support this conclusion (30). Nevertheless,
at present there is no single protocol defined for physical
therapy after decompressive spinal surgery in dogs, or which
sub-population (if any) is most likely to derive benefit, and so this
might need attention during a clinical trial. In large pragmatic
trials it would not be necessary to define specific physical therapy
protocols because the effects of any specific regimen would
be expected to randomize equally between treatment groups
amongst the large patient numbers, but this might not apply
in smaller trials. Similarly, use of other drugs before and after
surgery might also require controlling, or recording for inclusion
as an analytical covariable. For instance, glucocorticoids have
been examined for their effects in numerous studies (31),
albeit without strong evidence of effect. More recently, opiates,
specifically kappa opioids, have been implicated in worsening
outcomes in experimental animals with spinal cord injury (32).
OUTCOME ASSESSMENT
In every clinical trial it is imperative to define an outcome
measure that will be used to define whether the intervention
has achieved its goal of improving patient outcome. It is also
necessary that the outcome be defined BEFORE the trial so
as to prevent selective reporting after the data are collected,
implying that it requires careful consideration. Useful outcome
measures vary a great deal—between those that directly measure
a key outcome that is definitely important to a participant, such
as death—to those that are termed “surrogate outcomes” and
measure something related to a key outcome but is not that
key outcome—for instance, the area of MRI abnormalities in
the brain of patients that have multiple sclerosis [e.g., (33)]. A
pragmatic approach will use easily measured outcomes, which
might be loosely defined, whereas explanatory trials will aim to
quantify outcomes more precisely, often using relatively complex
schemes or equipment.
Specific Definitions Are Required
For spinal cord injury trials in dogs the most obvious outcome
measure would be the ability to walk, especially since that
is usually the lost function that encourages owners to seek
veterinary advice. There is much merit in using this as an
outcome measure, but there are some details that require
attention when designing a trial. For instance, what does “ability
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to walk” mean: how many consecutive steps defines a dog as
being “able to walk?” Does this apply to every walking surface?
The most difficult aspect when recording the ability to walk after
severe spinal cord injury in dogs is their ability to (sometimes)
develop the ability to “spinal walk”—which is usually defined
as the ability to walk without any clinical evidence of neural
communication between the head and the limbs (i.e., clinically,
dogs with persistent loss of deep pain sensation) [(29, 34) and
see Lewis et al., companion article in this issue]. In terms of
analysis of the effectiveness of a putative therapy, explanatory
trials would wish to exclude recovery that is mediated by “spinal
walking” because it does not reflect true regulation of locomotion
from the brain and cervical spinal cord (i.e., the trial question
is: “can the intervention restore the brain’s ability to control the
pelvic limbs?”). However, the pragmatic approach would be that
if the dog can walk it does not matter whether the dog is able
to voluntarily regulate this motion or not (i.e., the trial question
is: “can the dog get around the yard?”). Both are acceptable
outcomes but it is essential that these possibilities are considered
before the trial and that the appropriate measure is used to
address the question that is posed.
Recently the ability to “walk 10 (consecutive) steps” has
increasingly been taken as a relatively pragmatic indication of
recovery of locomotion [e.g., (35)]. Originally, this measure was
used because many dogs that spinal walk are not able to take as
many as 10 consecutive steps, although this does not encompass
ALL spinal walking dogs (see Lewis et al., this issue) and there
is also a question as to whether the flooring surface should be
considered too. One advantage of using the 10 step “convention”
is that by becoming a recognized standard the results of trials
carried out on different interventions can be (broadly) compared.
There is of course nothing special about 10 steps as opposed to 20
steps etc., but usually animals that can recover to walk 10 steps
can then also go on to improve and walk further.
Outcome Observer
The other question that has to be asked about a simple outcome
measure such as walking, is who will make the final decision on
the outcome? Will it be the owner or will it be a veterinarian,
or a specialist veterinarian? The answers that are given by each
may well be different. A specialist neurologist is much more
likely to identify spinal walking compared to an owner, and they
are much more likely to feel that the distinction is important.
Nowadays it might also be asked about whether the outcome
can be determined remotely: can the specialist running the trial
make a determination of whether a dog can walk (or urinate
voluntarily) by observing a video recording? Fortunately, recent
work has suggested that it is relatively straightforward to train
observers to a common outcome (36). A related question is the
blinding of outcome observers. It is critical that those running the
trial—and ideally owners too—are unaware of which treatment
arm their dog has been allocated to. The people running the
trial can reasonably be expected to be biased and owners might
also interpret outcome in light of wishing to find that the new
therapy is beneficial. Therefore, it is imperative that recording of
outcome is done by someone who is unaware of the treatment
allocation. This requirement can be problematic in veterinary
medicine because of the limited personnel available in many
clinics, including those trained to ask penetrating questions about
voluntary function observed in the dogs, or to carry out more
complex evaluations of function.
Although the ability to walk is an obvious and relevant
outcome measure there are many other approaches to outcome
assessment after spinal cord injury in dogs. In spinal cord injury
research on experimental animals, locomotor scoring schemes
have been applied for decades, most recently in the open-field
“BBB scale” that grades the use of each pelvic limb and the
coordination between thoracic and pelvic limb girdles (37).
Similar schemes have been devised for use in dogs (38, 39) and
all carry the advantage of allowing the quality of locomotion to
be assessed, so implying that grades of recovery can be measured.
However, there are also drawbacks, most notably that these
scores are not truly numerical (and so are ordinal rather than
continuous scales), which complicates interpretation (40), and
there is also a great deal of inter-animal variability in outcome,
even in rats that have incurred highly-regulated identical injuries
(41). In addition, although easily applied in practice, these scales
are designed to detect a surrogate outcome—one that is collected
for the purposes of a trial rather than to detect a useful clinical
benefit. The relationship between (small) improvement on these
scales and clinical function is uncertain.
Kinetics and kinematics provide even more finely graded
outcomes and kinematic analysis can be especially valuable
because it can imply conduction across a lesion in the
thoracolumbar area through detection of coordination of phase
patterns of thoracic and pelvic limb stepping (42). These
outcomes have been used to assess outcome in canine spinal cord
injury trials because they are able to detect subtle changes in
function (43, 44) that might realistically be expected to occur
following an intervention in severely and chronically affected
individuals. On the other hand, kinematic measures are clearly
surrogate outcomes, especially when applied to animals walking
on a treadmill, and it can also be argued that the detection
of small differences in function might not have much clinical
relevance. Again the choice here is outlined as a distinction
between pragmatic (“can the dog walk?”) and explanatory (“is
there a change in kinematics?”) outcomes and reiterate the
need to select the outcome that is most appropriate for each
individual trial.
Alternative outcomes, most notably bladder control, may
also be usefully examined. Many owners nowadays are not
all that concerned if their dog cannot walk, since they can
be adequately mobile in carts, but they may be much more
concerned about urinary control. There are many methods to
define urinary control, ranging from the pragmatic (e.g., “does
the dog urinate in the house?”) to more precise, but clinically
remote, outcomes such as bladder compliance (the ability of
the bladder to accommodate increasing urine volume). The use
of bladder compliance as an outcome for a canine spinal cord
injury trial has previously been described (44), although there are
currently gaps in knowledge regarding normal bladder function
in dogs (see companion article in this issue).
Finally, electrodiagnostic tests, particularly sensory and motor
evoked potentials that measure long tract function, can be used as
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outcome measures (44). These are clearly explanatory outcomes
and primarily used as an aid to interpreting mechanisms of
change in function associated with an intervention.
HOW MANY CASES WILL BE NEEDED?
The number of participants needed to be enrolled in a clinical
trial is determined by sample size calculations, which are
determined by the desired power of the study and the false
positive rate that is acceptable. There is also a difference in
numbers needed depending on whether the sample size will be
calculated based on a change in proportion reaching a specific
criterion, or whether a specified difference inmean values is used.
On the whole, power of clinical trials is set at 0.8 or 0.85 (i.e. β =
0.2 or 0.15) and the false positive value is usually set at 0.05 (i.e.
α = 0.05). The methods for calculating sample size are widely
available online and contained in various software packages as
well as in numerous publications [MedCalc.net (45)].
Sample size calculations also depend on the size of the
difference in outcome between groups that is being sought and
the variability in the measure between and within individuals.
Smaller differences in outcome and greater variability demand
larger sample sizes. Variability in outcome can occur because of
variability within and between individuals and can also result
from imprecision in measurement.
If determining sample size based on proportions reaching a
specified criterion (e.g., ability to walk 10 steps) it is necessary to
have a reasonable estimate of the outcome after standard therapy
(usually derived from previous publications) and to then estimate
the proportion that might recover following the test intervention.
This estimation is best derived from preliminary data, but can
also be based on what might realistically be useful in the clinic,
which might, in turn, depend on the invasiveness or toxicity of
that intervention. On the whole, if the proportion of the sample
that reach the criterion is close to 1 or 0 then sample sizes are
much smaller than they are for proportions close to 0.5. For
instance if we are to look at the proportion of deep pain dogs
recovering to walk after standard therapy (∼0.55) and consider
that improving this to 0.65 would be clinically worthwhile, then
the necessary sample size is ∼375 per group (assuming two-
sided testing with α = 0.05, β = 0.2). On the other hand, if we
were interested in reducing the proportion of deep pain negative
dogs that develop myelomalacia (current therapy is associated
with ∼0.15) to 0.05, then the sample size needed would be
∼138 per group. This statistical efficiency provides a reason to
be attracted to trials on very severely, and possibly chronically,
injured individuals that are unlikely to recover spontaneously
[see (46)].
Using the change in mean values between comparator groups
is more statistically efficient, but requires a numeric outcome
measure. It is also necessary to know (or estimate reasonably)
the mean and standard deviation of the intervention and control
groups. A problem that frequently arises is that it is difficult to
know how much change in the outcome measure is meaningful.
For instance, if we were to examine stride length as an outcome
(as is commonly used in experimental rodents), how much
change would be clinically meaningful for a paralyzed dog? The
other aspect is that this method is highly dependent on the
precision of measurement of the outcome. If there is a great deal
of variability the ability to be sure that there is a real difference
between groups is blunted. Similarly, if the outcome measure
turns out not to be normally distributedmany of the assumptions
in analysis will be breached (although data transformation can
often overcome this problem).
Whatever method is used the smaller the difference that is
sought, the larger the sample size needed. When calculating
sample size it is important that the sample size be realistic. Canine
spinal cord injury is very common and so many hundreds of
dogs can be accumulated, although that may require multicenter
collaboration to achieve. On the other hand, it is also important
that the difference between control and intervention group that
is sought should be realistic. Most treatments in medicine have a
moderate effect size and so, for instance, it is not realistic to power
a study to detect a 50% difference in recovery between groups of
deep pain negative dogs—no treatment is realistically going to be
that effective.
Pragmatic vs. explanatory approaches can differ in terms of
numbers needed in two main ways. First, an explanatory trial
might be expected to refine the entry criteria with the aim of
being able to discern even small differences between intervention
and control and the sample size might then be reduced (although
the selected cases will be a sub-set of the whole pragmatic
population). Second, pragmatic trials tend to rely on “intention-
to-treat” analysis in which all cases that enter the trial are
included, irrespective of whether they received their allocated
treatment or not. On the other hand, explanatory trials tend
to rely on “per protocol” analysis, in which only participants
that completely complied with the trial protocol are analyzed.
Reliance on per protocol analysis tends to increase the numbers
needed to achieve appropriate power because there will be many
participants lost between enrolment and analysis.
ANALYSIS
Well-designed simple parallel group clinical trials usually do
not require complicated statistical testing. Calculation of relative
risk for a specific outcome [e.g., see CRASH trial (47)], chi-
squared test or t-test (or non-parametric equivalent) is often
sufficient to answer the basic trial question. Sometimes baseline
measurement should be included as a covariate, necessitating use
of analysis of covariance methods (usually implying regression
techniques). Great care has to be taken with any sub-group
analysis, and sub-groups should not be analyzed unless they
are pre-specified and had relevant power calculations applied
before trial commencement. Much harm has occurred in humans
through misinterpretation of sub-group analysis (48). Similar
considerations apply to analysis of whole study groups for which
pre-trial sample size calculations are not available and for which
study power is unknown (49).
Exceptions that might require more complicated analysis
include the more complicated study designs such as crossover
or factorial trials. However, crossover trials will rarely be
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appropriate for analyzing effects of interventions for spinal
cord injury (especially acute injury, because time will be
assumed to have a strong effect) and factorial trials require
identification of interventions that might interact with each other
(otherwise they have no advantage over parallel group trials) and
there are few such combinations that have been identified in
laboratory science.
ETHICAL CONSIDERATIONS
The ethics of clinical trials in humans are complicated and
rigorously regulated by international treaties and numerous
guidelines (Helsinki Declaration: https://www.wma.net/
policies-post/wma-declaration-of-helsinki-ethical-principles-
for-medical-research-involving-human-subjects/). Those for
veterinary clinical trials are less tightly regulated but follow
the same basic principles: a trial needs to have a favorable
risk/benefit analysis such that animals are carefully protected
from detrimental consequences and have a reasonable chance of
benefit from an intervention. Both of these aspects are usually
addressed through investigations that precede the Phase II trial
and may include data collection from experimental animals and
Phase I studies in dogs. The question that inevitably follows is
how much information is required before a Phase II/III trial can
be considered reasonable and ethical. Similar questions have
been asked regarding trials in human spinal cord injury (50)
and the answer turns out to be different depending upon who is
asked (51). On the whole, trials participants are more eager to
press ahead with trials and researchers tend to be more cautious.
Beyond the requirement for preliminary data suggesting safety
and efficacy, design of the trial itself most be undertaken ethically
so as to ensure societal value of the information obtained. It is
essential that all outcome measures can be assessed appropriately
and that results of the study will be useful, which implies that
the results will be disseminated to the scientific community
by publication. Most clinical trial work in pet dogs requires
ethical oversight from the Institutional Animal Care and Use
Committee (IACUC) or a hospital review board at the center
that is coordinating the trial, plus informed caregiver consent.
Study review and approval generally includes assessment of
design and proposed outcomes, component analysis of protocol
activities that extend beyond the standard of care and how
risks associated with those are mitigated, examination of sample
size calculations, and investigator and personnel credentials and
training in animal care.
PRACTICAL OBSTACLES TO CLINICAL
TRIALS IN SPINAL CORD INJURY IN DOGS
There is a strong rationale for clinical trials on spinal cord
injury treatments in dogs and many have been carried out and
are readly accessible via PubMed (or other) searches using the
keywords “dog” “spinal cord injury” “trial.” It is readily apparent
that few fulfill all the appropriate requirements for an effective
clinical trial and many have design problems, such as lack of a
control group (or unclear controls), that limit their value. This
current review article is not intended to be a systematic review
of previously published trials for but instead provides a checklist
of items that can be applied by readers to evaluate each of the
previously published trials themselves. On the whole, the most
major problem has been the inability to recruit a sufficiently large
number of participants, mainly because trials have been located
at single centers. Challenges in multicenter trial design include:
logistical challenges of coordinating fee structures, study review
and approval across different sites; additional costs incurred by
incorporation of subawards into funding applications; lack of
availability and consistent infrastructure and equipment across
sites; need for reasonably consistent training and application
of trial methods at each center; barriers assumed to exist with
incorporation of trial methodologies into routine private referral
practice and the assumed traditional independent-mindedness
of veterinarians in general. Retention of recruited clients can
also be problematical, especially for spinal cord injury, for which
prolonged follow-up is essential. Many previously published
clinical trials in canine spinal cord injury are discussed in more
detail in the companion article in this issue “Ambulation in
dogs with absent pain perception after acute thoracolumbar spinal
cord injury.”
The main question is, how can obstacles to multicenter
trials be overcome? Answers might include simplifying trial
procedures so that many individuals and centers can be involved,
establishing groups with an appropriate democratic structure to
allow all collaborators to feel valued and involved in decision-
making and, importantly, securing funding that bonds groups
together and enables employment of trial-specific personnel.
POSSIBLE CLINICAL TRIAL DESIGNS IN




The focus of this review article is on clinical trials for treatment of
dogs with thoracolumbar spinal cord injury resulting from acute
disc herniation. Whilst there are strong arguments for carrying
out trials in dogs that have reached an unacceptable plateau
of recovery at a later date—because they definitely require new
therapies and the effect of new therapies might be more easily
detected (because the baseline recovery rate is so poor)—here
we will focus on two possible candidates for trials for dogs that
present with loss of “deep pain sensation” in the acute phase. We
have selected two candidate interventions that are “ready to go”
but have constructed contrasting trial designs to highlight the
many choices that need to be made. Although we describe here
an explanatory trial focused on glyburide and a pragmatic trial
focused on durotomy these specific approaches do not need to be
specifically linked in this way to these interventions.
(a) Glyburide, aka glibenclamide, is a hypoglycemic agent that
was used as an aid to controlling diabetes mellitus in people. It
also has effects on the Sur1/TrpM4 channel that is involved in
the progression of spinal cord tissue damage after acute contusion
Frontiers in Veterinary Science | www.frontiersin.org 7 September 2020 | Volume 7 | Article 583
Jeffery et al. Clinical Trial
TABLE 1 | Outline of two contrasting example approaches to spinal cord injury trials in dogs.
Explanatory Pragmatic
Population Chondrodystrophic dogs weighing <15 kg with 7 vertebral-length gap on
myelo MRI and serum GFAP >7 ng/mL, presenting within 24 h of when last
seen walking
Any deep pain negative dog
Intervention Glyburide 150 µg/kg, then 75 µg/kg TID for 3 days 4-vertebral length durotomy
Comparator Sham tablets prepared by pharmacy Standard care
Outcome Open-field score repeated at weekly intervals for 3 months Death or euthanasia by 3 weeks
Other restrictions Physical therapy applied to animals in both groups for 30min each day up
till 3 months
No rules on physical therapy and adjunctive
treatment
Personnel requirements Training in open-field score analysis. Monitoring of dogs 24/7 for signs of
hypoglycemia
No specific requirements
Analysis Regression/ANOVA to analyze time x treatment interaction effects on
open-field score over 3 month period
Chi-squared test to compare proportion of
all-cause deaths between groups
Animals included in analysis Only those that received glyburide at appropriate dose and times for 3 days,
received physical therapy according to protocol and have follow-up for all
time points until 3 months






Expecting a score of 10.7 in control group and 12 in the treated group, with
SD of 1.5, would require 22 per group
Expecting 15% deaths at 3 weeks in controls
and 5% in intervention group would require 138
per group




and its beneficial effects after spinal cord injury have been well-
documented in several neuroscience laboratories throughout
the world (52). Recently, pharmacokinetic studies have been
carried out in dogs, showing that it has a good safety margin
(hypoglycemia was not a problem at the doses needed to attain
appropriate serum concentrations) and allowing construction of
an appropriate dosing regimen for treatment of spinal cord injury
(53). This drug therefore appears to have many advantages: it is
widely available as a standard commercial preparation, it is cheap,
the pharmacokinetics and safety are acceptable for use in dogs
and it has shown benefit in many pre-clinical studies of spinal
cord injury.
However, one question regarding glyburide is whether we
would need to have a time limit on when trial dogs become
paraplegic before presentation. In experimental work with
glyburide, it would appear that it is most beneficial if it can be
given before about 8 h after injury (54). It can be problematical to
know for how long dogs have been paraplegic when the owners
find them and it can be problematical to get a dog into a specialist
clinic for treatment with a trial drug within the 8-h period. Also,
if we were to limit inclusion to dogs that presented within 8 h of
injury it would greatly reduce our expected recruitment numbers.
So the best plan may be to design the trial to accept any dog that
has become paraplegic and deep pain negative within 24 h, with
a pre-specified analysis of the sub-groups that present <12 and
12–24 h after paralysis.
(b) Durotomy has been posited as a treatment for acute
spinal cord injury since it was first modeled in animals in the
early twentieth century (55). Since then there have been several
studies suggesting that it is, or is not, helpful in dogs with acute
spinal cord injury (56–58). The great advantage that durotomy
appears to have is that, according to experimental data, the
effect of incising the dura persists over at least 3 days after the
injury (24), therefore perhaps making it more appropriate than
glyburide for translation into dogs. There is also the advantage
that anyone who is doing the decompressive surgery can carry out
this procedure without having to have additional study materials
or equipment.
Although there has been debate over the value of durotomy
as an additional decompressive technique that might aid in
restoring blood supply (and therefore retaining tissue integrity)
after spinal cord injury, there are now data supporting its efficacy
in clinically paralyzed dogs (25, 26).
How Might Dogs Be Randomized?
In large human clinical trials it is routine to use a central
telephone service that designates treatment to each patient as they
are enrolled. This method facilitates multicenter participation
but does demand high level staffing and funding. For many
veterinary trials for which funding at high levels (if at all) is
unavailable, simple randomization that is blocked by center
(i.e., each center has their own randomization) is still possible.
The most straightforward way to randomize is to prepare a set
of opaque envelopes, each containing the treatment allocation
on a slip of paper and made up in variable-sized batches
(so that the allocating clinician cannot predict what treatment
the next patient will receive when they get near the end
of a batch). The same procedure can be duplicated at each
participating center; it is important that each center should
randomly assign cases independently, to ensure that one center
does not allocate unevenly compared to another. It is essential
that clinicians who will allocate animals to treatment cannot
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knowwhich intervention each patient will receive until they open
the envelope (i.e., there is appropriate allocation concealment).
Numbering of envelopes also prevents allocations being selected.
How Might We Measure Outcome?
In these contrasting trials we have selected contrasting outcomes
for the two interventions. For the explanatory trial on glyburide
we have suggested using an open-field outcome assessment of
walking (38) that is applied at weekly intervals for 3 months.
These scores can then be assessed using repeated measures
ANOVA or equivalent regression analysis, preferably accounting
for the non-numerical nature of the outcome scores; animals
that die or are euthanased before 3 months will be excluded
from this analysis. For the durotomy trial we are interested
in possible effect of averting progressive myelomalacia and so
the simplest outcome to measure is whether dogs survive for
longer then 3 weeks (although this will inevitably include some
dogs euthanased for reasons apart from myelomalacia). The
proportion surving for longer than 3 weeks will be compared
between treatment groups using Fisher’s exact test.
Ethical Considerations
A question might also be asked about whether it can be regarded
as ethical to carry out a trial if preliminary studies show support
for efficacy of an intervention—most notably here regarding
durotomy. On the other hand, there may also be long (or even
short-term) adverse effects of the new intervention that have
not yet been detected and, furthermore, a principle of evidence-
based medicine is that new therapies should be rigorously tested
before widespread clinical adoption. It is also essential that all
participating centers and personnel are adequately trained and
equipped to carry out the trial procedures; training videos can
often be used to facilitate such preparation.
Another way of looking at the assumed outcomes of a
successful trial on durotomy is that if there really is an
improvement in outcome from 15 to 5% that are dead by 3 weeks
then this would suggest a number-needed-to-treat of 100/10 =
10, i.e., for every 10 animals that are treated by durotomy only
one additional animal survives for more than 3 weeks. While
this can be justified if the therapy is beneficial it does also mean
that there is little reason to be too concerned about allocating an
animal to standard care alone, especially considering that there
may also be adverse effects of the novel intervention (see above).
Another aspect is that an independent data and safety
monitoring committee should be established to oversee data
and, sometimes, to carry out interim analysis as it accumulates.
In the trials outlined in Table 1 this would only be realistic
for the pragmatic trial on durotomy (because the other trial
will enroll such a small number of cases). Such committees
often use statistical stopping rules to aid decisions on interim
analyses, to prevent a trial from continuing for too long if
there is an unexpected but obvious imbalance in outcomes—
an excess of benefit or of harm—before full trial recruitment
has occurred (59). However, stopping rules can be controversial
because stopping too early can lead to erroneous conclusions—
especially with a bias toward larger effect size—or fuel continuing
dispute regarding efficacy. One solution is to accept only extreme
differences between groups at early stages, with progressive
relaxation during the trial (60); the risks of multiplicity must
also be incorporated. A more nuanced, and modern, option is to
interpret interim results as a whole, taking into account statistics
on both primary and secondary outcomes, the relative risk benefit
and the problems that might arise in association with stopping
too early, in order to provide evidence that is “beyond reasonable
doubt” (61).
CONCLUSIONS
Large pragmatic clinical trials to determine the optimal methods
for treating dogs with spinal cord injury are undoubtedly
required. The relatively poor outcome associated with severe
(i.e., “deep pain negative”) thoracolumbar spinal cord injury
following acute intervertebral disc herniation is the most obvious
target. On the one hand, trials on such cases should mean
that any “signal” resulting from an intervention will be easy to
detect (because so little is expected of them); on the other, these
cases are the hardest nuts to crack and so it is less probable
that a detectable effect will be observed. Trials in less severely
affected animals produces the opposite problem: many cases
will get better anyway and so the signal of the intervention is
lost in the noise of spontaneous recovery. Similar considerations
apply to use of alternative outcome measures, including those
used to examine autonomic function. There are many candidate
therapies that could reasonably be tested and, worldwide, there
aremany affected dogs available for recruitment. Current barriers
are largely problems of our (i.e., veterinarians’) own making and
can feasibly be overcome.
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